Background/Aims: The association between chronic kidney disease (CKD) awareness and healthy behaviors is unknown. We examined whether CKD self-recognition is associated with healthy behaviors and achieving risk-reduction targets known to decrease risk of cardiovascular morbidity and CKD progression. Methods: CKD awareness, defined as a ‘yes’ response to ‘Has a doctor or other health professional ever told you that you had kidney disease?’, was examined among adults with CKD (eGFR <60 ml/min/1.73 m2) who participated in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Odds of participation in healthy behaviors (tobacco avoidance, avoidance of regular nonsteroidal anti-inflammatory drug use, and physical activity) and achievement of risk-reduction targets (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use, systolic blood pressure control and glycemic control among those with diabetes) among those aware versus unaware of their CKD were determined by logistic regression, controlling for sociodemographics, access to care and comorbid conditions. Systolic blood pressure control was defined as <130 mm Hg (primary definition) or <140 mm Hg (secondary definition). Results: Of 2,615 participants, only 6% (n = 166) were aware of having CKD. Those who were aware had 82% higher odds of tobacco avoidance compared to those unaware (adjusted OR = 1.82, 95% CI 1.02–3.24). CKD awareness was not associated with other healthy behaviors or achievement of risk-reduction targets. Conclusions: Awareness of CKD was only associated with participation in one healthy behavior and was not associated with achievement of risk-reduction targets. To encourage adoption of healthy behaviors, a better understanding of barriers to participation in CKD-healthy behaviors is needed.

Keywords:
Chronic kidney disease, Awareness, Self-management, Behaviors
1.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–612.
2.
Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX: Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006;17:2034–2047.
3.
Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 2003;42:1050–1065.
4.
Regalado M, Yang S, Wesson DE: Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension. Am J Kidney Dis 2000;35:687–694.
5.
Toyama K, Sugiyama S, Oka H, Sumida H, Ogawa H: Exercise therapy correlates with improving renal function through modifying lipid metabolism in patients with cardiovascular disease and chronic kidney disease. J Cardiol 2010;56:142–146.
6.
CMS Manual System, Coverage of Kidney Disease Patient Education Services: In: Department of Health and Human Services (DHHS) CfMMC (ed), 2009.
7.
Devins GM, Mendelssohn DC, Barre PE, Binik YM: Predialysis psychoeducational intervention and coping styles influence time to dialysis in chronic kidney disease. Am J Kidney Dis 2003;42:693–703.
8.
Manns BJ, Taub K, Vanderstraeten C, Jones H, Mills C, Visser M, McLaughlin K: The impact of education on chronic kidney disease patients’ plans to initiate dialysis with self-care dialysis: a randomized trial. Kidney Int 2005;68:1777–1783.
9.
Devins GM, Mendelssohn DC, Barre PE, Taub K, Binik YM: Predialysis psychoeducational intervention extends survival in CKD: a 20-year follow-up. Am J Kidney Dis 2005;46:1088–1098.
10.
Plantinga LC, Boulware LE, Coresh J, Stevens LA, Miller ER 3rd, Saran R, Messer KL, Levey AS, Powe NR: Patient awareness of chronic kidney disease: trends and predictors. Arch Intern Med 2008;168:2268–2275.
11.
Wright JA, Wallston KA, Elasy TA, Ikizler TA, Cavanaugh KL: Development and results of a kidney disease knowledge survey given to patients with CKD. Am J Kidney Dis 2011;57:387–395.
12.
Mason J, Khunti K, Stone M, Farooqi A, Carr S: Educational interventions in kidney disease care: a systematic review of randomized trials. Am J Kidney Dis 2008;51:933–951.
13.
Kuo HW, Tsai SS, Tiao MM, Liu YC, Lee IM, Yang CY: Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf 2010;19:745–751.
14.
Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med 2003;139:244–252.
15.
Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, Graham A, Moy CS, Howard G: The reasons for geographic and racial differences in stroke study: Objectives and design. Neuroepidemiology 2005;25:135–143.
17.
Standards of Medical Care in Diabetes – 2006. Diabetes Care 2006;29(suppl 1):S4–S42.
18.
Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247–254.
19.
Tuot DS, Plantinga LC, Hsu CY, Powe NR: Is awareness of chronic kidney disease associated with evidence-based guideline-concordant outcomes? Am J Nephrol 2012;35:191–197.
20.
Plantinga L, Grubbs V, Sarkar U, Hsu CY, Hedgeman E, Robinson B, Saran R, Geiss L, Burrows NR, Eberhardt M, Powe N: Nonsteroidal anti-inflammatory drug use among persons with chronic kidney disease in the United States. Ann Fam Med 2011;9:423–430.
21.
Miller MJ, Schmitt MR, Allison JJ, Cobaugh DJ, Ray MN, Saag KG: The role of health literacy and written medicine information in nonsteroidal antiinflammatory drug risk awareness. Ann Pharmacother 2010;44:274–284.
22.
Greer RC, Cooper LA, Crews DC, Powe NR, Boulware LE: Quality of patient-physician discussions about CKD in primary care: a cross-sectional study. Am J Kidney Dis 2011;57:583–591.
23.
Plantinga LC, Johansen K, Crews DC, Shahinian VB, Robinson BM, Saran R, Burrows NR, Williams DE, Powe NR: Association of CKD with disability in the United States. Am J Kidney Dis 2011;57:212–227.
24.
Whaley-Connell A, Sowers JR, McCullough PA, Roberts T, McFarlane SI, Chen SC, Li S, Wang C, Collins AJ, Bakris GL: Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 2009;53:S11–S21.
25.
Parmar MS: Time to differentiate ‘decreased kidney function’ from ‘kidney disease’: towards improving the definition of chronic kidney disease. Int Urol Nephrol 2012;44:493–497.
26.
Neutel CI, Campbell NR: Changes in lifestyle after hypertension diagnosis in Canada. Can J Cardiol 2008;24:199–204.
27.
Hedayati SS, Minhajuddin AT, Toto RD, Morris DW, Rush AJ: Prevalence of major depressive episode in CKD. Am J Kidney Dis 2009;54:424–432.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.